(That is CNBC Professional’s dwell protection of Monday’s analyst calls and Wall Avenue chatter. Please refresh each 20-Half-hour to view the most recent posts.) Two of the largest analyst calls on Monday got here throughout the pharmaceutical and clear power sectors. UBS raised its ranking on Teva Pharmaceutical, citing a powerful model pipeline . In the meantime, KeyBanc named hydrogen gasoline cell inventory Bloom Power a prime choose . Shares of Bloom Power had been little modified within the premarket, whereas Teva rose greater than 2%. Take a look at the most recent calls and chatter beneath. 5:52 a.m. ET: Deutsche Financial institution names Saia a prime choose Deutsche Financial institution named Saia certainly one of its prime picks on Sunday and reiterated its purchase ranking and $600 worth goal on the trucking firm. The inventory has already soared greater than 100% this 12 months, however analyst Amit Mehrotra thinks it may acquire one other 41% because of the firm’s “remarkably resilient” earnings energy. “What is even more remarkable about SAIA is that we’re projecting the company to grow EPS by 60% in 2024 and 2025,” the analyst wrote, noting that that is the second-best development charge inside its group of friends. “This growth potential, combined with earnings resiliency, have been key considerations of our steadfast bullish stance on SAIA and why it continues to be our top pick in 2024.” Particularly, market knowledge exhibits that Saia’s perceived prices are at present underneath the perceived worth of its companies — that means that there is room for a lot larger costs, Mehrotra added. — Lisa Kailai Han 5:45 a.m. ET: KeyBanc names Bloom Power a prime choose KeyBanc Analyst Sangita Jain named Bloom Power a prime “clean tech” play, elevating her worth goal on the inventory to $20 from $19. The brand new goal implies upside of 53%. “Rising demand for clean power from data centers, the trend toward industrial reshoring, and delayed interconnections of renewables all work in favor of BE as a provider of baseload, behind the meter, onsite clean power,” Jain wrote. “We believe that in an environment of elevated power prices, and time to power considerations, BE is well positioned to deliver on the targeted 30-35% top-line CAGR through 2031,” the analyst added. “BE’s fuel cells have proven commercial viability, come with an IP moat, and the co. is expected to be op. margin positive in ’23.” Bloom Power shares have struggled this 12 months, shedding 30.1%. BE YTD mountain BE in 2023 — Fred Imbert 5:45 a.m. ET: UBS upgrades Teva Pharmaceutical on sturdy model pipeline UBS sees potential in Teva Pharmaceutical’s upcoming pipeline of merchandise. The financial institution upgraded the inventory to purchase from impartial in a Monday word and lifted its worth goal to $13 from $11. This up to date forecast implies a 36% upside from the inventory’s $9.55 shut on Friday. “While the story in the past several years has been focused on Revenue/EBITDA stabilization, going forward we anticipate attention shifting to attractive brand assets, where investors get to participate in launch acceleration and pipeline de-risking catalysts,” wrote analyst Ashwani Verma. “Although sell-side expectations have come up on some brands/pipeline products, we believe that the stock is not pricing in brand transition.” Particularly, the analyst thinks that key manufacturers equivalent to Austedo, Uzedy and Ajovy will profit as the corporate shifts its focus towards development engine supply. The outcomes of two key scientific trials, anticipated within the second half of 2024, are additionally attributable to increase the corporate’s model pipeline. — Lisa Kailai Han